Dyne Therapeutics, Inc. develops investigational therapies for genetically driven neuromuscular diseases using its FORCE platform, which is designed to deliver payloads to muscle tissue and the central nervous system. Company news centers on clinical programs in Duchenne muscular dystrophy and myotonic dystrophy type 1, including z-rostudirsen, z-basivarsen, the DELIVER, ACHIEVE and HARMONIA studies, and preclinical work in additional neuromuscular diseases.
Recurring updates include clinical data presentations, FDA interactions and designations, financial results, cash-resource commentary, medical-conference abstracts, access-related research, investor conference participation and Nasdaq inducement equity grants.
Dyne Therapeutics (DYN) granted inducement equity awards to 17 newly hired employees under Nasdaq Listing Rule 5635(c)(4). The grants comprise stock options to buy up to 213,000 common shares and restricted stock units covering 67,200 common shares.
The options have a ten-year term and an exercise price equal to Dyne’s closing share price on the Nasdaq Global Select Market on November 17, 2026. Both types of awards are scheduled to vest over four years, subject to continued employment through the applicable vesting dates. The grants are governed by the award agreements and Dyne’s 2024 Inducement Stock Incentive Plan.
Dyne Therapeutics (Nasdaq: DYN) management is scheduled to participate in the Jefferies Global Healthcare Conference on November 16, 2026.
The fireside chat in London is scheduled for 2:30 p.m. GMT (9:30 a.m. ET). A live webcast will be available in the Investors & Media section of Dyne’s website, with a replay accessible for 90 days.
Dyne Therapeutics (Nasdaq: DYN) reported a third-quarter 2026 net loss of $193.6 million while advancing its neuromuscular disease programs. Loss per share widened to $1.06 from $0.76 a year earlier. Cash, cash equivalents and marketable securities totaled $1.134 billion; Dyne expects funding to last into Q2 2028.
Z-rostudirsen for exon 51 Duchenne muscular dystrophy is under FDA priority review, with a January 21, 2027 target action date. Dyne expects a potential Q1 2027 U.S. launch, assuming timely approval. Z-basivarsen showed functional improvement across multiple measures at 12 months in pooled ACHIEVE trial participants versus baseline, placebo and matched natural history controls. Dyne plans registrational expansion cohort results in Q1 2027 to support a potential Q3 2027 application for accelerated approval, and expects a potential H1 2028 launch, subject to priority review and timely approval.
Dyne Therapeutics (Nasdaq: DYN) granted inducement equity awards to 16 newly hired employees as a material inducement to accept employment.
The awards comprise options to purchase up to 290,100 shares and restricted stock units covering 92,300 shares. The option exercise price equals the stock’s closing price on October 20, 2026. Options have a ten-year term and vest over four years: 25% on the first anniversary of each employee’s start date, followed by 12 equal quarterly installments. Restricted stock units vest in four equal annual installments from each employee’s start date. Both schedules require continued service through the applicable vesting dates. The grants fall under Dyne’s 2024 Inducement Stock Incentive Plan and Nasdaq Listing Rule 5635(c)(4).
Dyne Therapeutics (Nasdaq: DYN) announced additional one-year Phase 1/2 ACHIEVE results showing functional improvement with z-basivarsen in myotonic dystrophy type 1.
The pooled dose group included 25–26 participants. At six months, video hand opening time, a measure of delayed muscle relaxation, decreased by 3.2 seconds versus a 0.4-second increase with placebo. At 12 months, sit-to-stand, walking/running, strength and patient-reported measures improved from baseline. No related serious treatment-emergent adverse events were identified.
The pooled analysis mixed dose exposures; only 8 of 26 participants received the registrational dose throughout the 12 months. Dyne expects registrational expansion cohort topline data in Q1 2027, intended to support a potential U.S. Accelerated Approval application in Q3 2027. Phase 3 HARMONIA is recruiting and is intended to confirm the findings.
Dyne Therapeutics (DYN) granted inducement equity awards to 14 newly hired employees under Nasdaq Listing Rule 5635(c)(4).
The awards include non-statutory stock options to purchase up to an aggregate of 278,100 shares of common stock at an exercise price equal to the closing price on Nasdaq Global Select Market on September 15, 2026, and restricted stock units covering an aggregate of 88,400 shares.
The stock options have a ten-year term and are scheduled to vest over four years, with 25% vesting on the first anniversary of each employee’s start date and the remainder vesting in 12 equal quarterly installments, subject to continued service. The restricted stock units vest over four years in four equal annual installments, also subject to continued service, under Dyne’s 2024 Inducement Stock Incentive Plan and related award agreements.
Dyne Therapeutics (DYN) will present additional one-year clinical data from the Phase 1/2 ACHIEVE trial of zeleciment basivarsen (DYNE-101) for myotonic dystrophy type 1 at the 31st Annual International Congress of the World Muscle Society and the 2026 Annual Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine, both running September 29–early October 2026.
Presentations will include 6- and 12‑month data from a pooled ACHIEVE multiple ascending dose group (N=25–26) spanning three dose regimens, 12‑month data from a propensity‑matched cohort (N=41–46) from the END‑DM1 natural history study, and updated ACHIEVE safety results. Dyne will also share the average baseline video hand opening time in the blinded ACHIEVE registrational expansion cohort (n=71) and continues to expect topline REC data in Q1 2027.
Dyne Therapeutics (DYN) will present preclinical data for four investigational Duchenne muscular dystrophy (DMD) therapies at the 27th Annual Neuromuscular Study Group Scientific Meeting from September 25-27, 2026, in San Antonio, Texas.
The development candidates DYNE-253, DYNE-245, DYNE-244 and DYNE-255 target DMD mutations amenable to exon skipping of exons 53, 45, 44 and 55, respectively, and are advancing into IND-enabling studies. All use Dyne’s FORCE™ platform, also applied in zeleciment rostudirsen (z-rostudirsen, DYNE-251), which is under FDA review for exon 51 DMD. Presented data will include in vitro exon skipping for all four candidates and in vivo pharmacokinetic and pharmacodynamic results for DYNE-253, including exon skipping and dystrophin levels in a Del52 DMD mouse model.
The poster, titled “Delivering for DMD: Leveraging the FORCE platform to deliver exon skipping oligonucleotides for a broad set of DMD patients,” will be presented on Friday, September 25, from 5:00–7:00 p.m. CT and made available on Dyne’s website.
Dyne Therapeutics (DYN)/b) will participate in three healthcare investor conferences in September 2026, each featuring a management fireside chat in New York, NY.Events include the 2026 Cantor Global Healthcare Conference on September 11 at 10:20 a.m. ET, the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 at 9:15 a.m. ET, and the Baird 2026 Global Healthcare Conference on September 15 at 10:50 a.m. ET. Live webcasts and 90-day replays will be available in the Investors & Media section of Dyne’s website.
Dyne Therapeutics (Nasdaq: DYN) granted inducement equity awards to 11 newly hired employees under Nasdaq Listing Rule 5635(c)(4). The awards include non-statutory stock options for up to 161,300 shares of common stock at the August 19, 2026 closing price and restricted stock units (RSUs) for 51,200 shares.
The stock options have a ten-year term and are scheduled to vest over four years, with 25% vesting on the first anniversary of each employee’s start date and the balance vesting in 12 equal quarterly installments, subject to continued service. The RSUs are scheduled to vest in four equal annual installments over four years, also subject to continued service. The grants were made under Dyne’s 2024 Inducement Stock Incentive Plan and award agreements.